Melanoma in dogs: treatment, prognosis and clinical trials

Dogs · USA & Canada

Understanding melanoma

Melanoma is a cancer of melanocytes, but the word alone does not tell you how dangerous it is. In dogs, many skin melanomas are relatively low risk, while oral, mucosal and some nail-bed melanomas are much more aggressive. The primary site and pathology are therefore essential before discussing prognosis or treatment.

What does the prognosis look like?

The outlook can range from cure after surgery to a cancer that is difficult to control. A completely removed, low-risk skin tumor may never return. Tumors with aggressive pathology, incomplete removal or spread to lymph nodes or lungs need a more guarded outlook and usually more than surgery alone. The pathology report and staging results are what allow the oncologist to place your dog between those two ends of the range.

What matters next

Make sure the diagnosis includes the exact site. A melanoma in haired skin, a nail bed, the mouth or another mucosal site can behave very differently. Once the site and pathology are clear, staging can be matched to the actual metastatic risk instead of treating every melanoma as the same disease.

Where are you now?

The melanoma is on a toe or nail bed

Digital melanoma carries more metastatic risk than many ordinary cutaneous melanomas. Regional lymph-node evaluation and chest staging become more relevant, and local control often requires definitive treatment of the digit.

The melanoma is oral or another mucosal site

Treat it as a higher-risk melanoma until staging says otherwise. Local control and metastatic staging both matter, and prognosis should not be borrowed from low-risk cutaneous melanoma.

It has recurred or spread

Re-stage before simply repeating the previous plan. Systemic or immune-based options may become more relevant, while local treatment can still help pain, bleeding, or function at a troublesome site.

If you are waiting for oncology

First make sure the melanoma is being classified by site rather than treated as one disease. A low-risk cutaneous melanoma, digital melanoma and mucosal melanoma have different staging needs and urgency. Preserve pathology material if confirmation or further testing may be needed.

Questions to ask your oncologist

Where exactly did this melanoma originate, and how aggressive is that site expected to be?
Do we need regional-node or chest staging for this location?
Is local treatment alone reasonable, or is systemic treatment worth discussing?

How the diagnosis may appear in the record

The exact primary site belongs in the diagnosis: haired skin, digit or nail bed, oral cavity, another mucosal surface, or eye. A poorly pigmented melanoma may be called amelanotic and may require immunohistochemistry. Behavior and staging cannot be inferred from the word melanoma without the site.

Changes to watch for at home

Watch the primary site for growth, bleeding, ulceration, pain, or recurrence and report enlarged nodes, coughing, breathing changes, or unexplained weight loss in higher-risk sites. A digital tumor can first appear as persistent nail loss, swelling, lameness, or a wound that does not heal.

How it is usually treated

Treatment depends mainly on where the melanoma began. A localized skin melanoma may be treated with surgery alone, while oral, digital or mucosal melanoma may need staging, more aggressive local treatment and discussion of systemic or immune-based options. The site matters more than the word melanoma by itself.

What can affect treatment choices

Primary site is the key factor. Skin, nail-bed, oral and other mucosal melanomas can behave very differently, so pathology, local control, lymph nodes and distant spread are interpreted in that context.

Tests that may matter

Testing should match the site. Pathology is central, and poorly pigmented tumors may need additional immunohistochemistry. For higher-risk sites such as oral or digital melanoma, lymph-node assessment and chest staging can be useful. Molecular testing is best reserved for a specific treatment or trial question.

Treatment options available now

4 options currently in our catalog.

Check eligibility

Evaluation of TLR agonist Z-007 in dogs with cancer

Cummings School of Veterinary Medicine, Tufts University · USA

Location

Henry and Lois Foster Hospital for Small Animals, 200 Westboro Rd, North Grafton, MA 01536

Study details

Recruiting

What is being offered: Dog study of IV or intratumoral Z-007 for solid tumors including carcinomas, sarcomas and melanoma. Public criteria include a generally 2–7 cm repeat-biopsy-accessible tumor plus medical/laboratory requirements; no prior immunotherapy or autoimmune disease. Investigator prescreening required.

Who may qualify: Confirmed cancer diagnosis required; Min weight kg: 7; Measurable

May not qualify if: Prior immunotherapy

Costs / coverage: 🟡 Partially funded. Z-007 treatment through Day 63 and treatment of Z-007/biopsy-related side effects are covered; other owner costs should be confirmed with Tufts.

Contact: clinicaltrials@tufts.edu

Official study / enrollment information →

Intratumoral vs IV Carboplatin with or without HIFU for Canine Melanoma

UT Southwestern Veterinary Research and Oncology Clinic · USA

Location

Veterinary Research and Oncology Clinic, 5801 Forest Park Rd, Dallas, TX 75235

Study details

Current

What is being offered: Intratumoral nanoparticle/microparticle carboplatin versus IV carboplatin with or without HIFU

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Planned chemo

May not qualify if: Prior chemo; Severe systemic disease

Costs / coverage: ⚪ Owner-paid. The protocol brochure states that owners fully pay for the study, although possible subsidies may be available.

Contact: Paige Neumann, Research Study Coordinator — 214-645-6221; VROC@UTSouthwestern.edu

Official study / enrollment information →

Compassionate-Use Protocol for Advanced Non-Resectable Tumors

UT Southwestern Veterinary Research and Oncology Clinic · USA

Location

Veterinary Research and Oncology Clinic, 5801 Forest Park Rd, Dallas, TX 75235

Study details

Current

What is being offered: Investigational therapy, chemotherapy, immunotherapy and combination approaches under a prospective compassionate-use protocol

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Min weight kg exclusive: 2.5; min expected survival weeks: 3 weeks; Adequate organ function

May not qualify if: Severe systemic disease

Costs / coverage: ⚪ Owner-paid. The protocol brochure states that owners fully pay for the study, although possible subsidies may be available.

Contact: Paige Neumann, Research Study Coordinator — 214-645-6221; VROC@UTSouthwestern.edu

Official study / enrollment information →

Single-fraction SABR for progressive canine lung metastases

Tufts Cummings School of Veterinary Medicine · USA

Location

Henry and Lois Foster Hospital for Small Animals, 200 Westboro Rd, North Grafton, MA 01536

Study details

Recruiting

What is being offered: Single highly focused radiation dose for dogs with 2–10 progressive pulmonary metastatic nodules. The primary tumor, regional nodes and any non-pulmonary metastases must already be controlled; progression must be documented over 6–8 weeks, and all progressive lung lesions at least 5 mm must be safely treatable. Prior systemic therapy is allowed; cytotoxic chemotherapy pauses around SABR, while tolerated targeted therapy or immunotherapy may continue with radiation-oncologist approval. Tufts prescreening is required.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Metastatic; Measurable lung metastases; Planned radiation

Costs / coverage: 🟡 Partially funded. The study covers SABR, the one-month follow-up, adverse-event rechecks related to lung toxicity, and up to $860 toward the 2–3-month CT visit. Owners pay pre-enrollment bloodwork, chest imaging, treatment-planning CT, and diagnostic confirmation.

Contact: Tufts Clinical Trials Office — clinicaltrials@tufts.edu; owner and referring-veterinarian prescreening questionnaires on the official page

Official study / enrollment information →